A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI.
Schlumberger M, et al. Among authors: allison r.
Clin Cancer Res. 2016 Jan 1;22(1):44-53. doi: 10.1158/1078-0432.CCR-15-1127. Epub 2015 Aug 26.
Clin Cancer Res. 2016.
PMID: 26311725
Clinical Trial.